<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821622</url>
  </required_header>
  <id_info>
    <org_study_id>C3441052</org_study_id>
    <secondary_id>TALAPRO-3</secondary_id>
    <secondary_id>2021-000248-23</secondary_id>
    <nct_id>NCT04821622</nct_id>
  </id_info>
  <brief_title>Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC</brief_title>
  <official_title>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination&#xD;
      with enzalutamide compared with placebo in combination with enzalutamide in participants with&#xD;
      DDR-deficient mCSPC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have 5 periods: prescreening, screening, double-blind treatment, safety&#xD;
      follow-up, and long-term follow-up.&#xD;
&#xD;
      Approximately 550 men with mCSPC will be randomized. Eligible participants will be randomly&#xD;
      assigned to either of 2 treatment groups as follows:&#xD;
&#xD;
        -  Talazoparib in combination with enzalutamide.&#xD;
&#xD;
        -  Placebo capsules identical in appearance to talazoparib capsules in combination with&#xD;
           enzalutamide.&#xD;
&#xD;
      Talazoparib or identical placebo treatment will be blinded. Enzalutamide (160 mg/day) will be&#xD;
      open label. The dose of talazoparib/placebo to be given in combination with enzalutamide is&#xD;
      0.5 mg once daily. Participants with moderate renal impairment (eGFR 30-59 mL/min/1.73 m2 by&#xD;
      the MDRD equation) at screening may be enrolled and the talazoparib/placebo dose will be 0.35&#xD;
      mg once daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">April 10, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>radiological Progression-Free Survival</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time from the date of randomization to first objective evidence of radiographic progression or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>randomization up to 4 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response in measurable soft tissue disease</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>proportion of patients with measurable soft tissue disease at baseline with objective response per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in measurable soft tissue disease</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>duration of responses in patients with measurable soft tissue disease at baseline per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) response</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>proportion of patients with PSA response grater than or equal to 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time from baseline to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of antineoplastic therapy</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>Time from randomization to initiation of antineoplastic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptomatic skeletal event</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time from randomization to first symptomatic skeletal event (symptomatic fractures, spinal cord compression, surgery or radiation to the bone whichever is first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate use for prostate cancer pain</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time from randomization to opiate use for prostate cancer pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>AEs and SAEs incidence by type and severity (graded by NCI CTCAE version 4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment of talazoparib</measure>
    <time_frame>Weeks 5, 9, 13, and 17</time_frame>
    <description>plasma concentrations of talazoparib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment of enzalutamide and its metabolite</measure>
    <time_frame>Weeks 5, 9, 13, and 17</time_frame>
    <description>plasma concentrations of enzalutamide and its metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between ctDNA burden and outcome</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>ctDNA burden at baseline and on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in pain symptoms - change from baseline</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>change from baseline in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in pain symptoms - time to deterioration</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time to deterioration in patient-reported pain symptoms per Brief Pain Inventory Short Form (BPI-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in cancer specific general health status - change from baseline</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>change from baseline in participant-reported general health status per EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in cancer specific global health status/QoL - change from baseline</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>change from baseline in patient-reported Global health status/QoL per EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in cancer specific global health status/QoL - time to definitive deterioration</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes in cancer specific symptoms - time to definitive deterioration</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>time to definitive deterioration in disease specific urinary symptoms per EORTC QLQ-PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome: cancer specific functioning, and symptoms - change from baseline</measure>
    <time_frame>randomization up to 3 years</time_frame>
    <description>change from baseline in PGI-S</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talazoparib plus enzalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus enzalutamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talazoparib plus enzalutamide</intervention_name>
    <description>experimental arm</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Combination arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus enzalutamide</intervention_name>
    <description>Active comparator arm</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Monotherapy arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male participants at least 18 years of age at screening (20 years for Japan).&#xD;
&#xD;
          2. Histologically or cytologically confirmed adenocarcinoma of the prostate without small&#xD;
             cell or signet cell features. If the participant does not have a prior histological&#xD;
             diagnosis, a baseline de novo biopsy must be used to confirm the diagnosis and may&#xD;
             also be used to support biomarker analysis.&#xD;
&#xD;
          3. Confirmation of DDR gene mutation status by prospective or historical analysis (with&#xD;
             sponsor pre-approval) of blood (liquid biopsy) and/or de novo or archival tumor tissue&#xD;
             using FoundationOne Liquid CDx or FoundationOne CDx.&#xD;
&#xD;
          4. Willing to provide tumor tissue when available (de novo or archived) for retrospective&#xD;
             molecular profiling analysis, if not already provided as part of inclusion criterion&#xD;
             3.&#xD;
&#xD;
          5. Unless prohibited by local regulations or ethics committee decision, consent to a&#xD;
             saliva sample collection for retrospective sequencing of the same DDR genes tested on&#xD;
             tumor tissue and blood (liquid biopsy), or a subset thereof, and to serve as a&#xD;
             germline control in identifying tumor mutations.&#xD;
&#xD;
          6. Surgically or medically castrated, with serum testosterone less or equal to 50 ng/dL&#xD;
             (less or equal to 1.73 nmol/L) at screening. Ongoing ADT with a GnRH agonist or&#xD;
             antagonist for participants who have not undergone bilateral orchiectomy must be&#xD;
             initiated at least 4 weeks before randomization and must continue throughout the&#xD;
             study.&#xD;
&#xD;
          7. Metastatic prostate cancer documented by positive bone scan (for bone disease) or&#xD;
             metastatic lesions on CT or MRI scan (for soft tissue). Participants whose disease&#xD;
             spread is limited to regional pelvic lymph nodes are not eligible. Note: a finding of&#xD;
             superscan at baseline is exclusionary.&#xD;
&#xD;
          8. Prior docetaxel therapy for mCSPC (up to 6 cycles) is allowed (must be completed 2&#xD;
             weeks prior to randomization and all toxicities from treatment have resolved).&#xD;
&#xD;
          9. Treatment with estrogens, cyproterone acetate, or first-generation anti-androgens is&#xD;
             allowed until randomization.&#xD;
&#xD;
         10. Other prior therapy allowed for mCSPC; ≤6 months of ADT and ≤3 months of approved NHT&#xD;
             in mCSPC (ie, abiraterone + prednisone, apalutamide, or enzalutamide), if required&#xD;
             prior to randomization.&#xD;
&#xD;
         11. Participant may have received palliative radiation or surgery for symptomatic control&#xD;
             secondary to prostate cancer, which should have been completed at least 2 weeks prior&#xD;
             to randomization.&#xD;
&#xD;
         12. ECOG performance status 0 or 1.&#xD;
&#xD;
         13. Adequate organ function within 28 days before the first study treatment on Cycle 1 Day&#xD;
             1, defined by the following:&#xD;
&#xD;
               -  ANC ≥1500/µL, platelets ≥100,000/µL, or hemoglobin ≥9 g/dL (may not have received&#xD;
                  growth factors or blood transfusions within 14 days before obtaining the&#xD;
                  hematology laboratory tests at screening).&#xD;
&#xD;
               -  Total serum bilirubin &lt;1.5 × ULN (&lt;3 × ULN for participants with documented&#xD;
                  Gilbert syndrome or for whom indirect bilirubin concentrations suggest an&#xD;
                  extrahepatic source of elevation).&#xD;
&#xD;
               -  AST or ALT &lt;2.5 × ULN (&lt;5 × ULN if liver function abnormalities are due to&#xD;
                  hepatic metastasis).&#xD;
&#xD;
               -  Albumin &gt;2.8 g/dL.&#xD;
&#xD;
               -  eGFR ≥30 mL/min/1.73 m2 by the MDRD equation.&#xD;
&#xD;
         14. Sexually active participants that in the opinion of the investigator are capable of&#xD;
             ejaculating, must agree to use a condom when having sex with a partner (female or&#xD;
             male) from the time of the first dose of study treatment through 4 months after last&#xD;
             dose of study treatment. Must also agree for female partner of childbearing potential&#xD;
             to use an additional highly effective form of contraception from the time of the first&#xD;
             dose of study treatment through 4 months after last dose of study treatment when&#xD;
             having sex with a non pregnant female partner of childbearing potential.&#xD;
&#xD;
         15. Must agree not to donate sperm from the first dose of study treatment to 4 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
         16. Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
         17. Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other acute or chronic medical (concurrent disease, infection or co-morbidity) or&#xD;
             psychiatric condition including recent (within the past year) or active suicidal&#xD;
             ideation/behavior or laboratory abnormality that interferes with a participant's&#xD;
             ability to participate in the study, may increase the risk of associated with study&#xD;
             participation or study treatment administration, or may interfere with the&#xD;
             interpretation of study results, and, in the investigator's judgment, make the&#xD;
             participant inappropriate for entry into the study.&#xD;
&#xD;
          2. History of seizure or any condition (as assessed by investigator) that may predispose&#xD;
             to seizure (eg, prior cortical stroke, significant brain trauma), including any&#xD;
             history of loss of consciousness or transient ischemic attack within 12 months of&#xD;
             randomization.&#xD;
&#xD;
          3. Major surgery (as defined by the investigator) within 2 weeks before randomization.&#xD;
&#xD;
          4. Known or suspected brain metastasis or active leptomeningeal disease.&#xD;
&#xD;
          5. Symptomatic or impending spinal cord compression or cauda equina syndrome.&#xD;
&#xD;
          6. Any history of MDS, AML, or prior malignancy except for the following:&#xD;
&#xD;
               -  Carcinoma in situ or non-melanoma skin cancer.&#xD;
&#xD;
               -  A cancer diagnosed and treated ≥3 years before randomization with no subsequent&#xD;
                  evidence of recurrence.&#xD;
&#xD;
               -  American Joint Committee on Cancer Stage 0 or Stage 1 cancer &lt;3 years before&#xD;
                  randomization that has a remote probability of recurrence in the opinion of the&#xD;
                  investigator and the sponsor.&#xD;
&#xD;
          7. In the opinion of the investigator, any clinically significant gastrointestinal&#xD;
             disorder affecting absorption.&#xD;
&#xD;
          8. Clinically significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction or symptomatic cardiac ischemia within 6 months before&#xD;
                  randomization.&#xD;
&#xD;
               -  Congestive heart failure New York Heart Association class III or IV.&#xD;
&#xD;
               -  History of clinically significant ventricular arrhythmias (eg, sustained&#xD;
                  ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1&#xD;
                  year before screening.&#xD;
&#xD;
               -  History of Mobitz II second degree or third-degree heart block unless a permanent&#xD;
                  pacemaker is in place.&#xD;
&#xD;
               -  Hypotension as indicated by systolic blood pressure &lt;86 mm Hg at screening.&#xD;
&#xD;
               -  Bradycardia as indicated by a heart rate of &lt;45 beats per minute on the screening&#xD;
                  electrocardiogram.&#xD;
&#xD;
               -  Uncontrolled hypertension as indicated by systolic blood pressure &gt;170 mm Hg or&#xD;
                  diastolic blood pressure &gt;105 mm Hg at screening. However, participants can be&#xD;
                  rescreened after adequate control of blood pressure is achieved.&#xD;
&#xD;
          9. Active COVID-19 infection detected by viral test or based on clinical diagnosis (as&#xD;
             assessed by investigator). Asymptomatic participants with no active COVID-19 infection&#xD;
             detected but positive antibody tests, indicating past infection are allowed.&#xD;
&#xD;
         10. Prior ADT in the adjuvant/neoadjuvant setting, where the completion of ADT was less&#xD;
             than 12 months prior to randomization and the total duration of ADT exceeded 36&#xD;
             months.&#xD;
&#xD;
         11. Participant received treatment with systemic glucocorticoids greater than the&#xD;
             equivalent of 10 mg per day of prednisone within 4 weeks prior to randomization,&#xD;
             intended for the treatment of prostate cancer.&#xD;
&#xD;
         12. Any previous treatment with DNA-damaging cytotoxic chemotherapy (ie, platinum based&#xD;
             therapy) within 5 years prior to randomization, except for indications other than&#xD;
             prostate cancer.&#xD;
&#xD;
         13. Prior treatment with a PARPi.&#xD;
&#xD;
         14. Prior treatment in any setting with NHT, except as described in Inclusion Criterion&#xD;
             #10.&#xD;
&#xD;
         15. Current use of potent P-gp inhibitors within 7 days prior to randomization. For a list&#xD;
             of potent P-gp inhibitors, and other medications which are exclusionary because of&#xD;
             interaction with either talazoparib or enzalutamide, refer to Section 6.5.&#xD;
&#xD;
         16. Treatment with any investigational study intervention within 4 weeks before&#xD;
             randomization. Exception: COVID-19 vaccines authorized under an emergency use&#xD;
             authorization (or equivalent) can be administered without a washout period.&#xD;
&#xD;
         17. Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may&#xD;
             affect participant safety or interpretation of study results (eg, QTcF interval &gt;450&#xD;
             msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction,&#xD;
             ST-T interval changes suggestive of myocardial ischemia, second or third degree AV&#xD;
             block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected&#xD;
             QT interval is &gt;450 msec, this interval should be rate-corrected using the Fridericia&#xD;
             method and the resulting QTcF should be used for decision making and reporting. If QTc&#xD;
             exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and&#xD;
             the average of the 3 QTc or QRS values should be used to determine the participant's&#xD;
             eligibility. Computer-interpreted ECGs should be overread by a physician experienced&#xD;
             in reading ECGs before excluding participants.&#xD;
&#xD;
         18. Investigator site staff or Sponsor employees directly involved in the conduct of the&#xD;
             study, site staff otherwise supervised by the investigator, and their respective&#xD;
             family members.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Institute of Urology, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology Research Clinic</name>
      <address>
        <city>Sherwood</city>
        <state>Arkansas</state>
        <zip>72120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute at MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group Hematology and Oncology</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services, Advent Health Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellstar Cobb Hospital</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica</name>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <zip>30117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital</name>
      <address>
        <city>Cartersville</city>
        <state>Georgia</state>
        <zip>30121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Urological Specialists, LLC</name>
      <address>
        <city>Chicago Ridge</city>
        <state>Illinois</state>
        <zip>60415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urologic Care, SC</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology &amp; Oncology Associates, Ltd</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute, Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute Inc.</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>David C. Pratt Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Cancer Care, P.A.</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute Clackamas Clinic</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute Newberg Clinic</name>
      <address>
        <city>Newberg</city>
        <state>Oregon</state>
        <zip>97132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Newberg Medical Center</name>
      <address>
        <city>Newberg</city>
        <state>Oregon</state>
        <zip>97132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute Franz Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Oncology and Hematology Care Clinic - Westside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keystone Urology Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkway Surgery Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Regional Medical Center</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ballad Health Cancer Care - Kingsport</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holston Valley Hospital and Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indian Path Community Hospital</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kelsey Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>oncology Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gallipoli Medical Research Foundation, Greenslopes Private Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epworth Freemasons-Epworth HealthCare</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Health, Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ (Algemeen Ziekenhuis) Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ (Algemeen Ziekenhuis) Sint-Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ (Algemeen Ziekenhuis) Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Stara Zagora Ltd.</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MRI SMDLOD &quot;Mediscan&quot; Ltd</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Prof. Dr. Stoyan Kirkovich&quot;</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Docrates Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oulun yliopistollinen sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valentis Cancer Hospital</name>
      <address>
        <city>Meerut</city>
        <state>Uttar Pradesh</state>
        <zip>250001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Netaji Subhas Chandra Bose Cancer Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>WEST Bengal</state>
        <zip>700094</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Romagnolo per lo Studio dei Tum.ori &quot;Dino Amadori&quot; (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili de Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hirosaki University School of Medicine &amp; Hospital</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba cancer center</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kure Medical Center and Chugoku Cancer Center</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokosukakyosai</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Meguro-Ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>State budget institution of healthcare of Mordovia Republic &quot;Republic Oncology Dispensary&quot;</name>
      <address>
        <city>Saransk</city>
        <state>Republic OF Mordovia</state>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Private Medical Institution &quot;Euromedservice&quot;</name>
      <address>
        <city>Pushkin</city>
        <state>Saint-petersburg</state>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;4D Ultrasound Clinic&quot; (LLC &quot;4D Ultrasound Clinic&quot;)</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol Region</state>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Arkhangelsk Region</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evimed Llc</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH &quot;Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Budgetary Healthcare Institution &quot;Ivanovskiy Regional Oncology Dispensary&quot; (RBHI &quot;IvROD&quot;)</name>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Russian Research Center of Roentgenology and Radiology&quot; of</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Medicina Severnoy Stolitsy&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Severo-Zapadny Medical Center&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UROEXAM, spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MILAB s.r.o.</name>
      <address>
        <city>Presov</city>
        <zip>08 001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Althaia, Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department</name>
      <address>
        <city>Kryviy Rih</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepion Medical Center</name>
      <address>
        <city>Khodosivka</city>
        <state>Kyivska Oblast</state>
        <zip>08173</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal non-profit enterprise &quot;Regional clinical hospital of Ivano-Frankivsk Regional Council&quot;</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comm Noncommerc Entp Lviv Reg Council &quot;Lviv Oncological Regional Therapeutical and Diagnostic Cntr</name>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3441052</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DDR</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>castration-sensitive</keyword>
  <keyword>PARP-inhibitor</keyword>
  <keyword>hormone-sensitive</keyword>
  <keyword>metastatic hormone-sensitive prostate cancer</keyword>
  <keyword>Advanced prostate cancer</keyword>
  <keyword>Metastatic castration-sensitive prostate cancer</keyword>
  <keyword>mCSPC</keyword>
  <keyword>enzalutamide</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <keyword>DNA Damage Response</keyword>
  <keyword>DNA Damage Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

